author-photo

Theodore Stewart Gourdin

Medical University of South Carolina

20

Papers

78

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Serial ctDNA profiling in patients with metastatic prostate cancer undergoing treatment with radium-223.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal.

2021 Current Opinion in Oncology
- Theodore Stewart Gourdin
Show All
- Source
- Cite
- Save
Citations (1)
Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials:

2019 Journal of Oncology Pharmacy Practice
Show All
- Source
- Cite
- Save
Citations (0)
Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

2019 Cancer
Show All
- Source
- Cite
- Save
Citations (23)
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy

2018 Seminars in Oncology
Show All
- Source
- Cite
- Save
Citations (37)